Susan E Knudson1, Divya Awasthi2, Kunal Kumar3, Alexandra Carreau4, Laurent Goullieux4, Sophie Lagrange4, Hélène Vermet5, Iwao Ojima6, Richard A Slayden7. 1. Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA. 2. Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA. 3. Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, NY 11794-3400, USA. 4. Sanofi-Aventis R&D, Infectious Disease Unit, 31036 Toulouse, France. 5. Sanofi-Aventis R&D, Drug Disposition, 34184 Montpellier, France. 6. Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, NY 11794-3400, USA. 7. Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA richard.slayden@colostate.edu.
Abstract
OBJECTIVES: The increasing number of clinical strains resistant to one or more of the front-line TB drugs complicates the management of this disease. To develop next-generation benzimidazole-based FtsZ inhibitors with improved efficacy, we employed iterative optimization strategies based on whole bacteria potency, bactericidal activity, plasma and metabolic stability and in vivo efficacy studies. METHODS: Candidate benzimidazoles were evaluated for potency against Mycobacterium tuberculosis H37Rv and select clinical strains, toxicity against Vero cells and compound stability in plasma and liver microsomes. The efficacy of lead compounds was assessed in the acute murine M. tuberculosis infection model via intraperitoneal and oral routes. RESULTS: MICs of SB-P17G-A33, SB-P17G-A38 and SB-P17G-A42 for M. tuberculosis H37Rv and select clinical strains were 0.18-0.39 mg/L. SB-P17G-A38 and SB-P17G-A42 delivered at 50 mg/kg twice daily intraperitoneally or orally demonstrated efficacy in reducing the bacterial load by 5.7-6.3 log10 cfu in the lungs and 3.9-5.0 log10 cfu in the spleen. SB-P17G-A33 delivered at 50 mg/kg twice daily intraperitoneally or orally also reduced the bacterial load by 1.7-2.1 log10 cfu in the lungs and 2.5-3.4 log10 cfu in the spleen. CONCLUSIONS: Next-generation benzimidazoles with excellent potency and efficacy against M. tuberculosis have been developed. This is the first report on benzimidazole-based FtsZ inhibitors showing an equivalent level of efficacy to isoniazid in an acute murine M. tuberculosis infection model.
OBJECTIVES: The increasing number of clinical strains resistant to one or more of the front-line TB drugs complicates the management of this disease. To develop next-generation benzimidazole-based FtsZ inhibitors with improved efficacy, we employed iterative optimization strategies based on whole bacteria potency, bactericidal activity, plasma and metabolic stability and in vivo efficacy studies. METHODS: Candidate benzimidazoles were evaluated for potency against Mycobacterium tuberculosis H37Rv and select clinical strains, toxicity against Vero cells and compound stability in plasma and liver microsomes. The efficacy of lead compounds was assessed in the acute murine M. tuberculosis infection model via intraperitoneal and oral routes. RESULTS: MICs of SB-P17G-A33, SB-P17G-A38 and SB-P17G-A42 for M. tuberculosis H37Rv and select clinical strains were 0.18-0.39 mg/L. SB-P17G-A38 and SB-P17G-A42 delivered at 50 mg/kg twice daily intraperitoneally or orally demonstrated efficacy in reducing the bacterial load by 5.7-6.3 log10 cfu in the lungs and 3.9-5.0 log10 cfu in the spleen. SB-P17G-A33 delivered at 50 mg/kg twice daily intraperitoneally or orally also reduced the bacterial load by 1.7-2.1 log10 cfu in the lungs and 2.5-3.4 log10 cfu in the spleen. CONCLUSIONS: Next-generation benzimidazoles with excellent potency and efficacy against M. tuberculosis have been developed. This is the first report on benzimidazole-based FtsZ inhibitors showing an equivalent level of efficacy to isoniazid in an acute murine M. tuberculosis infection model.
Authors: Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier Journal: Science Date: 2004-12-09 Impact factor: 47.728
Authors: Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley Journal: N Engl J Med Date: 2009-06-04 Impact factor: 91.245
Authors: E Lucile White; William J Suling; Larry J Ross; Lainne E Seitz; Robert C Reynolds Journal: J Antimicrob Chemother Date: 2002-07 Impact factor: 5.790
Authors: Laurel Respicio; Pravin A Nair; Qing Huang; Burcu Anil; Sylvia Tracz; James J Truglio; Caroline Kisker; Daniel P Raleigh; Iwao Ojima; Dennis L Knudson; Peter J Tonge; Richard A Slayden Journal: Tuberculosis (Edinb) Date: 2008-05-13 Impact factor: 3.131
Authors: Susan E Knudson; Jason E Cummings; Gopal R Bommineni; Pan Pan; Peter J Tonge; Richard A Slayden Journal: Tuberculosis (Edinb) Date: 2016-08-03 Impact factor: 3.131
Authors: Krupanandan Haranahalli; Simon Tong; Saerom Kim; Monaf Awwa; Lei Chen; Susan E Knudson; Richard A Slayden; Eric Singleton; Riccardo Russo; Nancy Connell; Iwao Ojima Journal: RSC Med Chem Date: 2020-10-16
Authors: Edgar Ferrer-González; Hyun Huh; Hassan M Al-Tameemi; Jeffrey M Boyd; Sang-Hyuk Lee; Daniel S Pilch Journal: J Bacteriol Date: 2021-07-22 Impact factor: 3.490
Authors: Sangmi Oh; Lena Trifonov; Veena D Yadav; Clifton E Barry; Helena I Boshoff Journal: Front Cell Infect Microbiol Date: 2021-03-15 Impact factor: 5.293